ONO-7913 Phase I Study (ONO-7913)
To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers.
Solid Tumor
BIOLOGICAL: ONO-7913
Dose-limiting toxicities, Number of participants with a DLT, 28 days|Adverse events, Assessed by the NCI CTCAE v5.0 criteria, Up to 24 months
Concentration vs time of ONO-7913 as single dose, PK profile, Up to 24 months
To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers.